AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Dr. Timothy Palzkill, professor of Pharmacology and Chemical Biology and Molecular Virology and Microbiology, and his research team have been studying mechanisms of resistance to the beta-lactam ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Infections by multidrug resistant organisms (MDROs) are a global health threat with a worrying increasing trend. In fragile ...

The appropriateness of combination therapy for infections caused by gram-negative ... resistant bacteria or fungi. There are no clinical data that suggest that the combination of a β-lactam ...

Bacterial cells can also make enzymes that chemically inactivate antibiotics; these include beta-lactamase ... when it comes to antibiotic resistance, gram-negative bacteria have an edge thanks ...

Gram-negative bacteria have three major resistance mechanisms to ... efflux pumps to expel antibiotics and beta-lactamase enzymes to inactivate beta-lactam antibiotics. New antibiotics must ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

The emergence of resistant to carbapenems Gram-negative bacteria (CR GNB) has severely challenged antimicrobial therapy. Many CR GNB isolates are only susceptible to polymyxins; however ...